ORAMED PHARMACEUTICALS INC (ORMP)
US68403P2039 - Common Stock
ORMP gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 198 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of ORMP have multiple concerns. ORMP is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year ORMP was profitable.
ORMP had a negative operating cash flow in the past year.
In the past 5 years ORMP reported 4 times negative net income.
In the past 5 years ORMP always reported negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 2.51%, ORMP belongs to the top of the industry, outperforming 86.73% of the companies in the same industry.
ORMP has a better Return On Equity (3.37%) than 86.73% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.51% | ||
| ROE | 3.37% | ||
| ROIC | N/A |
ROA(3y)-12.5%
ROA(5y)-20.94%
ROE(3y)-13.31%
ROE(5y)-29.78%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ORMP's Profit Margin of 412.39% is amongst the best of the industry. ORMP outperforms 100.00% of its industry peers.
The Operating Margin and Gross Margin are not available for ORMP so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 412.39% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ORMP does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ORMP has more shares outstanding
The number of shares outstanding for ORMP has been increased compared to 5 years ago.
The debt/assets ratio for ORMP is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 0.31, we must say that ORMP is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of ORMP (0.31) is comparable to the rest of the industry.
ORMP has a Debt/Equity ratio of 0.31. This is a healthy value indicating a solid balance between debt and equity.
ORMP has a Debt to Equity ratio (0.31) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.31 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.31 |
ROIC/WACCN/A
WACC7.57%
2.3 Liquidity
A Current Ratio of 3.06 indicates that ORMP has no problem at all paying its short term obligations.
With a Current ratio value of 3.06, ORMP perfoms like the industry average, outperforming 47.45% of the companies in the same industry.
ORMP has a Quick Ratio of 3.06. This indicates that ORMP is financially healthy and has no problem in meeting its short term obligations.
ORMP's Quick ratio of 3.06 is in line compared to the rest of the industry. ORMP outperforms 52.04% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.06 | ||
| Quick Ratio | 3.06 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 114.89% over the past year.
Looking at the last year, ORMP shows a very negative growth in Revenue. The Revenue has decreased by -50.37% in the last year.
ORMP shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -11.37% yearly.
EPS 1Y (TTM)114.89%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q250%
Revenue 1Y (TTM)-50.37%
Revenue growth 3Y-20.92%
Revenue growth 5Y-11.37%
Revenue growth Q2Q-100%
3.2 Future
The Earnings Per Share is expected to decrease by -48.90% on average over the next years. This is quite bad
Based on estimates for the next years, ORMP will show a very negative growth in Revenue. The Revenue will decrease by -14.87% on average per year.
EPS Next Y-289.43%
EPS Next 2Y-214.14%
EPS Next 3Y-123.6%
EPS Next 5Y-48.9%
Revenue Next Year-1.49%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
ORMP is valuated correctly with a Price/Earnings ratio of 15.71.
Compared to the rest of the industry, the Price/Earnings ratio of ORMP indicates a rather cheap valuation: ORMP is cheaper than 85.20% of the companies listed in the same industry.
ORMP's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 24.80.
ORMP is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.71 | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as ORMP's earnings are expected to decrease with -123.61% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-214.14%
EPS Next 3Y-123.6%
5. Dividend
5.1 Amount
No dividends for ORMP!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ORAMED PHARMACEUTICALS INC
NASDAQ:ORMP (4/18/2024, 7:12:32 PM)
After market: 2.26 +0.06 (+2.73%)2.2
-0.13 (-5.58%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap89.14M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.71 | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.51% | ||
| ROE | 3.37% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | 412.39% | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.31 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.06 | ||
| Quick Ratio | 3.06 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)114.89%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-289.43%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-50.37%
Revenue growth 3Y-20.92%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y